AbbVie lines up a new preclinical R&D alliance with the dealmakers at natural killer player
- maura169
- Nov 20, 2019
- 1 min read
Bill Haney is building on his rep as one of the most prolific dealmakers in preclinical R&D, adding a new alliance for Dragonfly Therapeutics with AbbVie on cancer drugs as well as autoimmune diseases — a new field for the upstart developer.
Komentarze